Main Menu
Untitled Page
Home > Equity > Company info > Company Snapshot
21 August 2017

Search Quotes

  Enter at least 3 characters from BSE Code for a company or the company's name

Aurobindo Pharma Ltd (Pharmaceuticals - Indian - Bulk Drugs & Formln)

Last Price 708.50
Net Changes 3.75
Volume 398158
Prev Close 704.75
708.50 3.75 (0.53%)
Date: Aug 21,2017 10:04:58




Index Details Pharmaceuticals - Indian - Bulk Drugs & Formln


Chart

Stock Price Details

Market Statistics

Open Price 711 Div Yield (%) 0.45
Buy (Size) 707.85(×280) Eps(Rs) 27.7
Sell (Size) 708.70(×84) Book Value(Rs) 143.9909803
Buy Quantity 280 Market Cap(Rs.Cr) 41275.42
Sell Quantity 84 Face Value(Rs) 1
Today's High 715.65 Market Lot 1
Today's Low 705.4 AGM Date Aug
52-Week High 895 Book Closure Date Aug
52-Week Low 504 ISIN No. INE406A01037

Share Holding Pattern

  No Of shares % Share Holding
Total Foreign (Promoter & Group) 18000000 3.07
Indian (Promoter & Group) 285925934 48.80
Total of Promoter 303925934 51.87
Non Promoter (Institution) 198079348 33.81
Non Promoter (Non-Institution) 83877127 14.32
Total Non Promoter 281956475 48.13
Total Promoter & Non Promoter 585882409 100.00
Custodians(Against Depository Receipts) 0 0.00
Grand Total 585882409 100.00

Company News

18-Aug-2017  Aurobindo Pharma Limited - Analysts/Institutional Investor Mee...
Aurobindo Pharma Limited - Analysts/Institutional Investor Meet/Con. Call Updates

Aurobindo Pharma Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates
10-Aug-2017  Aurobindo Pharma recovers after Wednesday's slide
Aurobindo Pharma recovers after Wednesday's slide

Meanwhile, the S&P BSE Sensex was down 197.82 points or 0.62% at 31,600.02.

On the BSE, 2.52 lakh shares were traded on the counter so far as against the average daily volumes of 3.46 lakh shares in the past one quarter. The stock had hit a high of Rs 722.05 and a low of Rs 701 so far during the day. The stock had hit a record high of Rs 895 on 6 October 2016 and a 52-week low of Rs 504 on 29 May 2017.

The stock had underperformed the market over the past one month till 9 August 2017, sliding 1.83% compared with the Sensex's 1.39% rise. The stock had, however, outperformed the market over the past one quarter, gaining 14.86% as against the Sensex's 6.23% rise. The scrip had underperformed the market over the past one year, sliding 10.48% as against the Sensex's 13.22% rise.

The large-cap company has equity capital of Rs 58.59 crore. Face value per share is Rs 1.

Shares of Aurobindo Pharma had declined 5.84% in a single trading session yesterday, 9 August 2017 to settle at Rs 684.15, ahead of announcing Q1 results.

Aurobindo Pharma's consolidated net profit fell 11.4% to Rs 518.50 crore on 2.3% decline in revenue from operations to Rs 3678.70 crore in Q1 June 2017 over Q1 June 2016.

EBITDA (earnings before interest, taxation, depreciation and amortization) before forex and other income fell 5.3% to Rs 841.60 crore in Q1 June 2017 over Q1 June 2016. EBITDA margin contracted to 22.9% in Q1 June 2017, from 23.6% in Q1 June 2016.

The company's Managing Director N. Govindarajan said that its key markets continue to maintain its momentum in both YoY and QoQ despite headwinds. It expects the momentum to sustain going forward driven by changing product mix towards complex products. It remains focused on strengthening its existing businesses and developing a differentiated and specialty driven product basket, Govindarajan said.

Separately, Aurobindo Pharma said after market hours yesterday, 9 August 2017 that it will increase its stake in Tergene Biotech to 80% from 60% by subscribing additional 56.50 lakh equity shares of Rs 10 each at par aggregating to Rs 5.65 crore. Tergene Biotech was a 60:40 joint venture between the company and promoters of Tergene.

Aurobindo Pharma manufactures generic pharmaceuticals and active pharmaceutical ingredients.

10-Aug-2017  Aurobindo Pharma standalone net profit declines 21.41% in the...
Aurobindo Pharma standalone net profit declines 21.41% in the June 2017 quarter

Net profit of Aurobindo Pharma declined 21.41% to Rs 307.33 crore in the quarter ended June 2017 as against Rs 391.03 crore during the previous quarter ended June 2016. Sales declined 9.99% to Rs 2131.78 crore in the quarter ended June 2017 as against Rs 2368.41 crore during the previous quarter ended June 2016.

ParticularsQuarter Ended
 Jun. 2017Jun. 2016% Var.
Sales2131.782368.41 -10
OPM %22.0423.92 -
PBDT490.01573.42 -15
PBT406.62503.02 -19
NP307.33391.03 -21
10-Aug-2017  Aurobindo Pharma consolidated net profit declines 11.36% in th...
Aurobindo Pharma consolidated net profit declines 11.36% in the June 2017 quarter

Net profit of Aurobindo Pharma declined 11.36% to Rs 518.51 crore in the quarter ended June 2017 as against Rs 584.96 crore during the previous quarter ended June 2016. Sales declined 2.25% to Rs 3621.07 crore in the quarter ended June 2017 as against Rs 3704.60 crore during the previous quarter ended June 2016.

ParticularsQuarter Ended
 Jun. 2017Jun. 2016% Var.
Sales3621.073704.60 -2
OPM %22.7224.00 -
PBDT840.50891.98 -6
PBT709.32785.74 -10
NP518.51584.96 -11
10-Aug-2017  Other announcement of Aurobindo Pharma Ltd.
Other announcement of Aurobindo Pharma Ltd.

We would like to inform you that Tergene Biotech Private Limited is a 60:40 joint venture between the Company and promoters of Tergene. As agreed among the JV Partners, the Company will increase its stake in Tergene Biotech Private Limited from 60% to 80% by subscribing additional 56,50,000 equity shares of Rs.10 each at par aggregating to Rs.5.65 crores.
10-Aug-2017  Aurobindo Pharma Limited - Press Release
Aurobindo Pharma Limited - Press Release

Aurobindo Pharma Limited has informed the Exchange regarding a press release dated August 09, 2017, titled 'Press Release on Aurobindo Pharma Ltd Q1 FY17-18 Financial Results'.
10-Aug-2017  Aurobindo Pharma Limited - Investor Presentation
Aurobindo Pharma Limited - Investor Presentation

Aurobindo Pharma Limited has informed the Exchange regarding Investor Presentation
10-Aug-2017  Aurobindo Pharma Limited - Updates
Aurobindo Pharma Limited - Updates

Aurobindo Pharma Limited has informed the Exchange regarding Transfer of land of the Company to the wholly owned subsidiary .
09-Aug-2017  Aurobindo Pharma to invest Rs 5.65 cr in JV Tergene Biotech
Aurobindo Pharma to invest Rs 5.65 cr in JV Tergene Biotech

Aurobindo Pharma announced that Tergene Biotech is a 60:40 joint venture between the Company and promoters of Tergene. As agreed among the JV Partners, the Company will increase its stake in Tergene Biotech from 60% to 80% by subscribing additional 56,50,000 equity shares of Rs.10 each at par aggregating to Rs.5.65 crore.
09-Aug-2017  Other announcement of Aurobindo Pharma Ltd.
Other announcement of Aurobindo Pharma Ltd.

Sub: Investors/Analysts Presentation Please refer to our letter dated 05.08.2017, wherein we have intimated the schedule of Investors/Analysts call on 10.08.2017. In this connection, we enclose herewith the presentation to the Investors/Analysts on the Unaudited Financial Results of the Company for the First Quarter ended 30.06.2017. The presentation is also being uploaded on the website of the Company - http://www.aurobindo.com/investor-relations/investors/investor-presentation Please take the information on record.
Incorporation Year 1986 
Registered Office Plot No 2 Maitrivihar,Behind Maithri Vanam Ameerpet,
Hyderabad,
Telangana-500038
Telephone 91-40-23736370 
Fax 91-40-23747340 
Chairman K Ragunathan
Managing Director N Govindarajan
Company Secretary B Adi Reddy 
Auditor S R Batliboi & Associates LLP 
Face Value(Rs)
Market Lot
Listing MCX-SX,BSE,NSE 
Registrar Karvy Computershare Pvt Ltd
Karvy Selenium Tow-B,Pl-31&32 Gachibowli,Nanakramguda,Hyderabad-500032 
Toll Free number: 1800-425-5501 / 1800-103-5501
FINANCIAL TOOLS